Skip to main content

Table 1 Baseline characteristics of included patients at baseline and after two cycles treatment.

From: On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

 

Patients enrolled at baseline

Patients enrolled after two cycles treatment

 

(n=134)

(n=121)

Age

  

Median (range), years

64 (34-74)

64 (34-74)

  ≥65 years

79 (59%)

67 (55%)

  <65 years

55 (41%)

54 (45%)

Sex

  

  Male

128 (96%)

116 (96%)

  Female

6 (4%)

5 (4%)

Smoking history

  

  ≥400 cigarette-years

117 (87%)

107 (88%)

  <400 cigarette-years

6 (4%)

5 (4%)

Never

11 (9%)

9 (8%)

ECOG performance status

  0

25 (19%)

21 (17%)

  1

109 (81%)

100 (83%)

Disease stage

  

  IIIB/IIIC

40 (30%)

34 (28%)

  IV

94 (70%)

87 (72%)

  Liver or brain metastases at enrollment*

0 (0%)

0 (0%)

  Liver metastases

14 (10%)

14 (12%)

  Brain metastases

2 (1%)

2 (2%)

PD-L1 tumor proportion score

  <1%

61 (46%)

57 (47%)

  ≥1%

70 (52%)

61 (50%)

  1-49%

36 (27%)

37 (31%)

  ≥50%

34 (25%)

24 (20%)

Not evaluable

3 (2%)

3 (2%)

  1. Data are n (%), unless otherwise indicated. * No patients with both liver and lung metastases were enrolled. ECOG, Eastern Cooperative Oncology Group